This article is more than 5 years old. Information may no longer be current.
High-dose intravitreal triamcinolone acetonide treats macular edema for up to 6 months
Click Here to Manage Email Alerts
One injection of decanted high-dose intravitreal triamcinolone acetonide can provide a 6-month treatment for patients with treatment-resistant persistent macular edema, according to a study.
Researchers examined the effects of decanted high-dose intravitreal triamcinolone acetonide 20 mg/0.1 mL on 77 eyes of 70 patients with macular edema. Thirty-six eyes had macular edema secondary to intraocular surgery of pars plana vitrectomy or trabeculectomy.
The mean ETDRS score at baseline was 38.7 letters. The mean improvement from baseline was 6.3 letters at 3 months, 6.8 letters at 6 months and 4.8 letters at 12 months.
Follow-up was for 1 year, and 63.6% of eyes required only one injection during this time. When reinjection was needed, it occurred at a mean of 6 months after the first injection.
“In conclusion, decanted [high-dose intravitreal triamcinolone acetonide] is an inexpensive, highly effective treatment option for persistent, treatment-resistant [macular edema] due to various retinal diseases. In 63% of eyes, the [macular edema] completely resolved after a single injection of decanted [high-dose intravitreal triamcinolone acetonide] and stabilized for up to 6 months,” the researchers wrote. – by Robert Linnehan
Disclosures: The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts